virnext

🔬 Handling of clinical and preclinical samples.   virnext offers services for the processing and analysis of clinical and preclinical samples. Our expertise includes: - RNA/DNA extraction - Respiratory pan-viral detection, identification and genome quantification -Viral load quantification (PFU, TCID50, Immunostaining) -Microneutralisation assays and histopathological scoring   We can process a wide range of infectious complex biological samples in BSL-2 and BSL-3 facilities, including: - Nasal wash and bronchoalveolar lavage - Oropharyngeal and nasopharyngeal swabs - Tissues and organs.   Contact us for more information: contact@virnext.fr https://www.virnext.fr/   #Preclinical #Clinical #Research #molecular #biology #Biotech #Virology #infectious #disease #respiratory #viruses

virnext at BioFIT Event 2024 – Final day We’re entering the final day of BioFIT 2024, and we are grateful for the many meaningful conversations, quality meetings, and interresting conferences we had yesterday. There is still time to come to Stand B22, where Virnext is presenting its expertise and know how in the field of respiratory viruses and preclinical research. We will be delighted to meet you and discuss how we might support your R&D with: · Production of high-quality, characterized viruses and viral vaccine antigens in egg and cell-based systems · Evaluation of therapeutic and prophylactic candidates in different preclinical models of respiratory virus infections · Virology services for the analysis and characterization of complex biological and clinical samples For more information: www.virnext.fr #BioFIT2024 #Virnext #Virology #Innovation #Collaboration #R&D #Science

virnext at BioFIT Event 2024! The BioFIT Event has officially started, and Virnext is ready to meet you at Stand B22. We look forward to presenting our expertise in emerging and re-emerging respiratory viruses as well as our continuum of in vitro and in vivo preclinical models of infection, and discussing how we can support your research and development projects. · Production of high-quality, characterized viruses and viral vaccine antigens in egg and cell-based systems · Evaluation of therapeutic and prophylactic candidates in different preclinical models of respiratory virus infection · Virology services for the analysis and characterization of complex biological and clinical samples For more information : www.virnext.fr #BioFIT2024 #Virnext #Virology #Innovation #Collaboration #R&D #Science

virnext is very proud to have contributed to this innovative solution for fighting pneumovirus infections ! The synergy of virnext’s expertise in respiratory viruses, preclinical in vitro and in vivo models and facilities, alongside the expertise of the #LVMC at Centre de recherche du CHU de Québec-Université Laval, has enabled the development and preclinical validation of the versatile Live-Attenuated Vaccine platform #METAVAC®. This platform addresses the critical public health challenges posed by seasonal epidemic pneumovirus infections. virnext's commitment aligns with national and European strategies for achieving sovereignty in protecting against emerging and re-emerging infectious diseases. It also supports the development of French industries and start-ups like Vaxxel in the Région Auvergne-Rhône-Alpes and boosts their international competitiveness. International Research Laboratory #RESPIVIR France - Canada, Université Claude Bernard Lyon 1, Université Laval, EZUS LYON, LYON INGENIERIE PROJETS, PULSALYS, Région Auvergne-Rhône-Alpes, Vaxxel Contact us for more information : contact@virnext.fr https://www.virnext.fr/ #virus #pneumovirus #infectiousdiseases #science #biotechnology #research #respiratory #vaccine #preclinical

🌟 virnext at BioFIT Event 2024! 🌟 We are thrilled to announce that virnext will be attending the BioFIT Event 2024 on 3-4 December 2024 in Lille! This event will be an excellent opportunity to exchange on R&D programs and explore potential collaborations. We look forward to presenting our expertise in emerging and re-emerging respiratory viruses as well as our continuum of in vitro and in vivo preclinical models of infection, and discussing how we can support your research and development projects. 📍 If you’re attending, don’t hesitate to come and meet us! https://lnkd.in/gJrr22P https://virnext.fr/ #BioFIT2024 #Virnext #Virology #Innovation #Collaboration#science

With ten years of expertise in the field of respiratory virus production, virnext offers a panoply of solutions and deliverables, such as viral supernatant, concentrated or highly purified virus, inactivated virus and quantified vaccine antigen split. Several systems of production are implemented, including adherent and suspension cell cultures ranging from the flask to the 2L bioreactor and embryonated hen eggs. Complete characterization of each production batch includes quantification (PFU, TCID50, EID50, genome copies, SRID, HAI, NAI, ELISA) and complete genome sequence. Upload the brochure about Virnext’s respiratory virus production https://lnkd.in/etie76r5 Contact us for more information: contact@virnext.fr https://www.virnext.fr/ Université Claude Bernard Lyon 1, EZUS LYON, LYON INGENIERIE PROJETS, Région Auvergne-Rhône-Alpes. #virus #antigen #vaccine #bioproduction #infectiousdiseases #viralproduction #science #biotechnology #research #respiratory #antiviral #preclinical

At virnext, we offer predictive preclinical models of respiratory virus infection to evaluate prophylactic and therapeutic candidates. These in vitro tissue models of the human upper or lower airway epithelium are cultured at the air-liquid interface (Epithelix). We have fully characterized these models for respiratory virus infections, including #Influenza virus, #SARSCOV2 variants, #RSV, and #HMPV. virnext provides a wide range of technologies, such as TEER measurement, viral quantification (RT-qPCR, TCID50, PFU), cytokine release measurement, immune gene expression analysis (RT-qPCR), and microscopy observation (CIQLE (Centre d'Imagerie Quantitative Lyon Est)), all within BSL-2 and BSL-3 facilities.   🔗 For more information and to discuss your specific needs, visit our website www.virnext.fr or contact us at contact@virnext.fr.   #Virology #RespiratoryViruses #PreclinicalModels #DrugDevelopment #VaccineResearch #InfectionModels #SARSCoV2 #Influenza #RSV #HMPV #ResearchInnovation #VirNext

At virnext, we offer predictive preclinical models of respiratory virus infection to evaluate prophylactic and therapeutic candidates. These in vitro tissue models of the human upper or lower airway epithelium are cultured at the air-liquid interface (Epithelix). We have fully characterized these models for respiratory virus infections, including #Influenza virus, #SARSCOV2 variants, #RSV, and #HMPV. virnext provides a wide range of technologies, such as TEER measurement, viral quantification (RT-qPCR, TCID50, PFU), cytokine release measurement, immune gene expression analysis (RT-qPCR), and microscopy observation (CIQLE (Centre d'Imagerie Quantitative Lyon Est)), all within BSL-2 and BSL-3 facilities.   🔗 For more information and to discuss your specific needs, visit our website www.virnext.fr or contact us at contact@virnext.fr.   #Virology #RespiratoryViruses #PreclinicalModels #DrugDevelopment #VaccineResearch #InfectionModels #SARSCoV2 #Influenza #RSV #HMPV #ResearchInnovation #VirNext

virnext offers support in the design of protocols and the implementation of preclinical studies, using several in vitro and in vivo models of infection, to develop and evaluate innovative strategies for containment and control of emerging and re-emerging respiratory viruses. virnext has developed in vitro cell-based models of infection and offers several assays for screening compounds, antibody or antiviral candidates on a large panel of viral strains. For high fidelity virus/drug evaluation, virnext has fully characterized several in vitro predictive models of infection using reconstituted human airway epithelium cultured at the air liquid interface (Epithelix®). virnext also proposes several in vivo models of #influenza, #SARSCoV2 and #pneumovirus infections dedicated to the evaluation of immunogenicity and efficacy of drug or vaccine candidates. Upload the brochure about Virnext’s preclinical models of viral respiratory infection: https://lnkd.in/e9xRDtGS Contact us for more information: contact@virnext.fr https://www.virnext.fr/ Université Claude Bernard Lyon 1, EZUS LYON, LYON INGENIERIE PROJETS, Région Auvergne-Rhône-Alpes, #Virpath. #sciences #biotechnology #research #infectiousdisease #virus #respiratory #vaccine #antigen #antiviral #preclinical

As an expert in respiratory viruses and in the antiviral field, virnext provides services in virology to analyze and characterize complex biological and clinical samples and proposes a full panoply of in vitro and in vivo antiviral assays against human and animal respiratory pathogens in BSL-2 and BSL-3 facilities. virnext offers a complete characterization of batches of several strains and seeds of interest or splits of antigens by Plaque Forming Unit assay (PFU), end-point dilution quantification of infectious viral particles on cells (TCID50) and eggs (EID50), hemagglutination assay (HA), fluorometric neuraminidase inhibition assay (NAI) and single radial immuno-diffusion assay (SRID). For the evaluation of antiviral and vaccine candidates, virnext also set up a wide range of technologies such as Hemagglutination Inhibition (HAI), MicroNeutralization (MN), enzyme-linked immunosorbent assay (ELISA), as well as viral load quantification from various respiratory samples with clinical and histopathological scoring. Find the list of standardized virological techniques and tests proposed by virnext by uploading the brochure: https://lnkd.in/eH-bTWgg Contact us for more information: contact@virnext.fr https://www.virnext.fr/ Université Claude Bernard Lyon 1, EZUS LYON, LYON INGENIERIE PROJETS, Région Auvergne-Rhône-Alpes. #sciences #biotechnology #research #infectiousdisease #virus #respiratory #vaccine #antigen #antiviral #preclinical #molecularbiology #sequencing #influenza, #RSV, #metapneumovirus, #adenovirus, #coronavirus, #parainfluenza #rhinovirus